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ABSTRACT	
Germline mutations on the CDKN2A gene, the most important known genetic factors associated with 
cutaneous melanomas (CMs), predispose carriers to multiple primary CMs (MPMs) with higher 
frequency and younger onset compared to non-carriers. Most of the largest published studies 
concerning clinical and histological characteristics of CMs with CDKN2A mutation carriers did not 
specify if the described CMs are first or subsequent to the first, and they used sporadic CMs from non-
genotyped patients as controls. 	
We conducted a single-centre observational study to compare clinical and histological CM features of 
32 unrelated carriers (MUT) of 5 germline CDKN2A mutations (one of which was never previously 
described) compared to 100 genotyped wild-type (WT) patients. We stratified the data based on time of 
diagnosis, anatomical site and histological subtype of CMs, demonstrating several significant 
unreported differences between the two groups. MUT developed a higher number of dysplastic nevi 
and MPMs.  We proved for the first time that anatomical distribution of CMs in MUT was independent 
of gender, unlike WTs. MUTs developed in situ and superficial spreading melanomas (SSMs) more 
frequently, with significantly higher number of SSMs on the head/neck. In MUTs, Breslow thickness 
was significantly lower for all invasive CMs. When CMs were stratified on the basis of the time of 
occurrence, statistical significance was maintained only for SSMs subsequent to the first. In WTs, 
Clark level was significantly higher, and ulceration was more prevalent than in MUTs. Significant 
differences in ulceration were observed only in SSMs. In nodular CMs, we did not find differences in 
terms of Breslow thickness or ulceration between WTs and MUTs. 	
In situ CMs developed 10 years earlier in MUTs with respect to WTs, whereas no significant 
differences were observed about invasive CMs. In contrast to those reported previously by other 
authors, we did not find a difference in skin phototype. 	
Keywords: CDKN2A, familial melanoma, cutaneous melanoma, melanoma susceptibility genes, risk 
factor for cutaneous melanoma	
Abbreviations: CM: Cutaneous Melanoma; PC: Pancreatic Cancer; MUT: carrier of CDKN2A 
germline mutation; WT: Wild-Type; UM: Uveal Melanoma; FCS: Familial Cancer Syndrome; 
N_CM1: First CM; N_CM1.5: CM diagnosed within 3 months after the first (Metachonous CM); 
MPMs: Multiple primary melanomas; SLNB: sentinel node biopsy; y: years; SNM: sentinel node 
metastases. 	
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INTRODUCTION	
To date, the major risk factor identified for cutaneous melanoma (CM) is a positive family history of 
this malignancy, which is reported in 5-15% of all melanoma patients [7,34,35]. Familial melanoma 
represents a genetically heterogeneous cancer, and several susceptibility genes during the last two 
decades have been identified. Autosomal dominant inherited germline mutations in the high-risk 
susceptibility genes, CDKN2A and, less frequently, CDK4, are the most important genetic factors 
associated with CM. Mutations in these genes are associated with an increased risk for both melanoma 
and pancreatic cancer (PC), recognized as “Melanoma-Pancreatic Cancer Syndrome” [24,34,35]. 
Pathogenic variants of CDKN2A have also been associated with an increased risk of other non-
melanoma and non-PC tumours (overall 75% of the carriers at age 80 years): gastrointestinal (upper 
tract) and respiratory malignancies, childhood cancers (nephroblastoma and acute lymphoblastic
leukaemia), squamous cancers of the head and neck and central nervous system tumours (recognized as 
“Melanoma and Neural System Tumour Syndrome”) [24,34,35]. In CDKN2A carriers (MUT), cancers 
also appear to be strongly influenced by environmental risk factors. CM risk has been positively 
associated with sun exposure, whereas pancreas, respiratory or upper digestive neoplasms are up to 9 
times more frequent in ever-smoking carriers compared with never-smoking carriers [21].  
Several studies, summarized in Table 1, reported clinical and histological features of CMs in CDKN2A 
mutation carriers, which differed significantly from melanomas of non-pathogenic CDKN2A variant 
carriers. Nonetheless, limited data are available about certain clinical and histological characteristics of 
skin tumours of CDKN2A mutation carriers. Particularly, most of these studies have not specified if the 
compared CMs are first (index cases) or subsequent (incident cases) cases, and they have are used as 
controls sporadic CMs developed by non-genotyped patients. This finding may lead to bias since most 
melanoma-prone families are, unlike most sporadic cases, under close dermatologic surveillance with
the aim to of diagnose tumours at earlier or premalignant stages [2,25,31,36,39].  
Moreover, germline mutations in additional susceptibility genes that confer a genetic risk for familial 
CM and non-cutaneous tumours have been identified. BAP1 acts as a tumour suppressor gene, and its 
germline mutations were reported to predispose patients to uveal (UM) and cutaneous melanoma, 
mesothelioma, renal cancer (RC), PC and basal cell carcinoma [1,5,10,12,40]. MITF confers an 
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increased risk for CM, RC, and PC; promoter of TERT and POT1 demonstrated co-segregation with 
CM-prone families [8,19,22,23, 28,29,32]. 
We conducted a single-centre observational study to identify carriers of germline mutations in 
melanoma susceptibility genes (CDKN2A, CDK4, MITF, promoter of TERT, BAP1 and POT1) in 
Caucasian patients with a history of CM undergoing periodic visits at our Department.  
The main objectives of this study were to outline the clinical and histological characteristics of CMs 
developed by carriers of these mutations, investigating the missing clinical and histological data. The 
more precise characterization of the hereditary oncologic phenotype of these melanoma-prone families 
could allow a better definition of a specific dermatological surveillance programme for mutation 
carriers and their family members.   
MATERIALS AND METHODS	
Enrolment of Cutaneous Melanoma cases 	
We enrolled 300 histologically confirmed CM patients who have undergone dermatologic surveillance 
at our Institution. In detail, the follow-up schedule was based on AJCC staging according to the 
guidelines developed by the major Italian referral centres for melanoma, and it was applied regardless 
of the mutational status [29]. For AJCC stage I, the programme consisted of a total-body physical 
examination every 6 months for the first 5 years and thereafter yearly with no radiological procedures. 
For AJCC stage II, clinical examination was performed every 4 months in the first 5 years, then every 6 
months from the 5th to the 10th year, and yearly after 10 years from the first diagnosis. For stage IB, an 
annual chest radiograph and abdomen ultrasound was performed for the first 5 years, whereas stage II 
patients underwent a computed tomography scan (TC). For stage III patients, imaging with FDG-PET 
and/or HR-TC scan was performed every 6 months for the first 5 years and then yearly [14,18].	
All patients were interviewed about their personal and family history of CM and non-CM tumours. 
Specifically, patients who had at least one of the inclusion criteria (Table 2) that suggests a FCS 
(Familial Cancer Syndrome) were considered eligible for genetic testing. 	
This study obtained approval by the Ethics Committee of our Institution (Comitato Etico 
Interaziendale, Azienda Ospedaliero Universitaria Maggiore della Carità di Novara, Italy). Written 
informed consent for study participation was obtained from all patients.	
Data Collection	
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We included 45% of 300 CM patients, which represented a sub-population of 134 non-related subjects 
at high risk not only for CM but also for other visceral cancers (high-risk patients). These patients were 
invited to participate in this study and were informed about its aims and limits. After providing written 
informed consent, peripheral blood for mutation analysis was obtained from all 134 high-risk patients.  	
All CM patients were Caucasian (131 of Italian descent, 1 Albanian, 1 Romanian and 1 Czech) and 
living in Italy. Clinical and histological cancer features, tumour site, disease stage, and age at diagnosis 
of CM was obtained from medical records, and a review of pathologic material and pathology reports 
was conducted for all CM patients. Familial recurrence of CM was checked using a questionnaire to 
interview patients about their first-, second-, and third-degree relatives. 	
Genotyping of candidate genes 	
We collected and processed blood samples as previously described in detail [10]. Genomic DNA was 
extracted using QIAamp® DNA Blood Maxi Kit (QIAGEN, Valencia, CA, USA) according to the
manufacturer’s protocol. Primers appropriately designed using the reference sequences provided by 
NCBI or Ensembl databases were used to amplify the exons and intron–exon boundaries of CDKN2A 
(NM_000077.4), the exon 2 of CDK4 (NM_000075.3), the promoter of TERT (NM_198253.2), the 
missense variant p.Glu318Lys of MITF (NM_000248.3), the 17 exons, intron–exon boundaries and 
promoter region (~1000 bp upstream of the ATG) of BAP1 (NM_004656.2) and exon 10 of POT1 
(NM_015450). PCR reactions were performed in a 25 μL tube using GoTaq® Flexi Polymerase 
(PROMEGA, Madison, WI, USA) for BAP1 fragment amplification and a Taq Gold 360 + GC 
enhancer for fragment amplification of melanoma predisposition genes.	
Statistical analysis	
Statistical analysis was performed to evaluate clinical and histological differences in CMs between 
carriers and non-carriers of germline mutations in melanoma-susceptibility genes. 	
The distribution of continuous variables was assessed with Q-Q plots. Mean and standard deviation
(SD) were estimated for continuous variables providing visual impression of normality. For these 
variables, the difference between study groups was assessed using Student’s t-test. Median and 
interquartile range (IQR) were estimated for continuous variables that did not provide visual 
impressions of normality. For these variables, the difference between study groups was assessed using 
the Wilcoxon Mann-Whitney U-test. Differences in the distributions of categorical variables between 
study groups were assessed using Fisher’s exact tests. All reported p-values are two-sided. 	
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RESULTS	
Mutational Analysis	
Among the 300 histologically confirmed CM patients who have undergone dermatologic surveillance 
at our Department between 2011 to 2016, 134 have been genotyped because they met at least one of the 
inclusion criteria (Table 2) suggesting a FCS.	
We identified 32 unrelated patients that were carriers of 5 different germline mutations (1 of which is a 
novel mutation) on the CDKN2A gene, and 1 patient (NFV20.1) was a carrier of a missense variant of 
the CDKN2A gene that has never been previously described in melanoma (Online Resource1); we also 
identified a patient with a unique BAP1 deleterious variant previously published (NFp101.1) [10].	
None of 134 patients were positive for any pathogenic germline variants on CDK4, MITF, the promoter 
of TERT or POT1. 	
The overall frequency of CDKN2A gene germline mutations in our series was 11%, accounting for
25% (33/133) of the selected high-risk patients. 	
Personal and Family Features of CDKN2A carriers	
To investigate the distinctive clinical and histological features of CM from carriers (MUT) versus non-
carriers (WT) of germline CDKN2A mutations, we compared the available data from the 32 MUT (21 F 
65%, 11 M 35%) versus the 100 WT patients (67 F, 33 M). We excluded patients NFV20.1 and 
NFp101.1 from the statistical analysis due to their unique genetic and clinical features (Online 
Resource 1). Therefore, we analysed 132 CM patients (88 F 66.7%, 44 M 33.4%) affected by 179 CMs.	
Skin phototype, family history, clinical and histological data of CMs, and melanocytic and atypical 
nevi are summarized in Tables from 3 to 6. 	
Gender	
The percentage of women (F) was significantly higher both among MUTs (65.7% P=0.05) and WTs 
(67%, P<0.001). Moreover, women developed most CMs regardless of genotype (71.7%, P=0.005 and
68%, P<0.001, respectively, in MUT and WT groups). 	
Phototype	 	
We did not find significant differences between the two genotyped groups (P=0.759). According to the 
phenotypic characteristics most represented in our geographical area, most patients had Fitzpatrick skin 
phototype III, which was observed in 59.4% of MUTs and 65% of WTs, respectively, while 25% of 
MUTs and 19% of WTs presented with Fitzpatrick skin phototype II.		
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Dysplastic nevi and common melanocytic nevi	
There was no difference in the number of total common melanocytic nevi (P=0.131). However, a 
personal history of previously excised dysplastic nevi was more frequent in MUT patients (62.5%); the 
comparison to the WT group (26%) showed a statistically significant difference (P<0.001). 	
Family History of CM and PC	
A positive family history of CM and/or PC was detected in 90.6% (29/32) of MUTs and in 37% 
(37/100) of WTs (P<0.001). There was a statistically significant difference between the two genotyped 
groups in term of CM family history (MUT 78.1% vs WT 29%, P<0.001) and PC family history (MUT 
34.4% vs WT 10%, P<0.001). Forty-one percent (54/132) of all patients included in this study had at 
least one relative with a history of CM. Among them, 46.3% (25/54) carried a CDKN2A germline 
mutation. Sixteen percent (21/132) of patients had almost at least one family member with a history of 
PC. Among them, 52.4% (11/21) carried a CDKN2A germline mutation.
Clinical Tumour Features of CDKN2A carriers 	
Age at diagnosis of CM 	
Considering both overall CMs and the first CM alone (N_CM1), we did not find a statistically 
significant difference between MUT and WT patients in the median age at diagnosis. However, the 
median age at diagnosis of in situ CM was approximately 10 years lower in MUTs than in WTs (Table 
3). All CMs diagnosed before the age of 20 occurred among MUT patients. The percentage of CMs 
diagnosed within 40 years was 60.5% in MUTs and 45% in WTs. 	
Moreover, MUTs developed metachronous CMs (e.g., diagnosed within 3 months from the first one 
N_CM1.5) at a lower median age (29 y) compared to WTs (43 y; p=0.053) (Table 3).	
Multiple primary melanomas (MPMs) 	
MUTs developed a statistically significant higher number of MPMs compared to WTs (Table 3). 
Although in both groups most of the patients developed 2 primary melanomas (61% among MUT,
87.5% among WT), 3 MPMs were observed more frequently in MUT than in WT subjects (28% vs 
12.5%), and 4 MPMs were observed in 11% of MUT patients and in none of the WTs. The time 
interval between first and subsequent to the first melanoma was longer in MUT than in WT subjects. In 
detail, 27.7% (5/18) of MUTs developed N_CM2 after > 5 y from the first one compared to 18.75% 
(3/16) of WTs (P=0.993). 	
Anatomical Site of CMs 	
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Overall, the anatomical site most frequently involved in CMs was the trunk, followed by lower limbs, 
upper limbs, head, and neck region and acral sites without statistically significant differences between 
the two genotyped groups (MUT vs WT, P=0.288). Regarding the MUT group, the pattern of skin 
involvement was similar in F and M subjects (P=0.685). Contrarily, in WT subjects, the involved body 
sites were significantly different by gender (P=0.008; Table 3 and 4). 	
Concerning MPMs, most MUT patients (77.8%) developed multiple CMs at different anatomical sites, 
whereas in the WT population, only 47% of patients showed discordant body sites (P=0.057).	
Histological Tumour Features of CDKN2A carriers 	
Histopathological features of CMs are summarized in Table 5 and 6 according to CDKN2A gene status. 	
Histological subtype 	
Overall, most CMs were SSMs (85%) followed by NMs (11%) and then by the other subtypes (4%), 
without statistically significant differences (P=0.512). As can be observed in Table 6, among invasive
CMs, the percentage of SSMs was higher in MUT than in WT patients (92% vs 83%, P=0.156), 
whereas NMs were more represented in WTs (15% vs 6%, P=0.086). 	
Considering only the first invasive tumours, SSM was the more frequently observed histotype (88.5% 
of MUT and 81% of WT patients, P=0.382). On the other hand, NMs were more represented in the 
non-carrier group (11.5% in MUT vs 16.5% in WT subjects; P=0.545).	
Globally, the frequency of in situ CMs was similar in the 2 groups (13.8% vs 14.9% of all CMs in 
MUT and WT). For only the first CMs, in situ CMs were more frequent in MUT patients (13.4% MUT 
vs 11.2% WT; P=0.758), and they were diagnosed at an earlier median age (34.5 y) compared to WTs 
(43 y). For subsequent CMs, we did not detect NMs; WTs developed in situ tumours more frequently 
than MUTs (P=0.068), who most commonly developed SSMs (P=0.061).	
Stratifying histological data based on the anatomical site, we observed differences in the distribution of 
CMs for the head and neck region: all MUT patients developed SSMs, while WT patients generated
mostly NMs or LM-LMMs (P=0.006). For the other anatomic sites, we did not observe statistically 
significant differences between the two groups. However, on lower limbs, 93.7% of MUT patients 
developed SSMs or in situ CMs (vs 76.3% of WT patients), while the 86% of NMs were found in WT 
patients.  	
Analysing MPMs, we noted that all patients, regardless of mutational status, tend to develop CMs with 
the same histological type (concordance of subtype of MPMs 63.2% MUT vs 70.8% WT P=0.594). 	
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Breslow thickness and Clark level	
MUT patients developed invasive CMs with significantly lower Breslow thickness than WTs. The 
results were significant both for all invasive CMs (median 0.4 mm vs 0.57 mm, P=0.023) and 
considering only the invasive CMs (all SSMs) after the first (mean 0.37 mm vs 0.73 mm, P=0.015). 
Among all invasive CMs, the percentage of lesions thicker > than 1 mm was 12.2% in MUTs and 32% 
in WT patients. Contrarily, as regards only first invasive CMs, carriers compared to non-carriers 
developed skin tumours with higher Breslow thickness, both for all tumours regardless of subtype (1.04 
mm vs 0.99 mm P=0.808) and for SSMs (0.96 mm vs 0.84 mm P=0.663). As regards NMs, we did not 
observe differences between MUT and WT patients (P=0.926).	
Regarding the Clark level, the difference between MUT and WT patients was statistically significant 
for all invasive CMs (P=0.002), for first invasive CMs (P=0.029) and for the invasive CMs subsequent 
to the first (P=0.005). In all, 69.4% of CMs from MUT subjects were Clark level II compared to 39.2%
of CMs from WT patients. In contrast, only 2% of CMs in MUT patients had a Clark level of IV, 
compared to 20.6% in the WT group. 	
Ulceration	
Considering all invasive CMs, a histologically confirmed ulceration was found in 1.8% of MUTs and 
11.9% of WTs (P=0.028). In contrast, considering only the SSMs, ulceration was presented exclusively 
in CMs from WT patients (P=0.036).	
For all NMs, we did not observe differences between MUT and WT patients. 	
Mitotic rate	
Mitotic rate (number of mitoses/mm2) was evaluable for 55.5% (86/179) of CMs, all diagnosed 
between 2009 and 2016 when this histological feature was introduced as a prognostic factor in the 
seventh edition AJCC Staging System [4]. We did not observe a statistically significant difference 
between the two genotyped groups: 74% vs 67% of all invasive CMs developed by MUT and WT
patients, respectively, had less than 1 mitoses/mm2 (P=0.168). We did not find differences comparing 
first invasive and subsequent to the first invasive CMs. 	
Regression 	
We did not find significant differences in regression comparing the two genotyped groups: the majority 
of CMs, regardless of mutational status, had no regression (92.7% MUT vs 93% WT of CMs; 
P=0.944). 	
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Sentinel node metastases (SNMs)	
Twenty-seven patients (15.6% among MUT and 22% among WT, P=0.436) met inclusion criteria for 
sentinel node biopsy (SLNB). None of the 5 MUT patients who underwent this procedure showed 
metastases (Stage II). Conversely, 18.2% of WTs (4/22) had SNMs (Stage III). However, we did not 
observe a statistically significant difference in relation to CDKN2A gene status (P=0.302). 	
DISCUSSION	
In this paper, we characterized the genetic status of 134 CMs Caucasian patients with respect to the 
most frequent melanoma susceptibility genes known at present. We found 32 carriers of CDKN2A 
germline mutations (one of which was previously unpublished) and 1 carrier of a unique CDKN2A 
variant; we also identified a carrier of a unique BAP1 variant previously described by our group [10].	
Our study confirms that germline mutation of CDKN2A is the main and most frequent genetic 
susceptibility factor for CM. In contrast, other genes such as CDK4, MITF, BAP1, promoter of TERT
and POT1, which none of the studies published to date and cited in Table 1 has investigated, are 
probably involved much more rarely. 	
Herein, we compared the clinical and histopathological features of CMs from 32 carriers of CDKN2A 
germline mutations and 100 non-carriers, demonstrating several significant differences between the 
two groups.  	
Our data highlight the overall female predominance in subjects affected by CM. Although the 
CDKN2A germline mutation is transmitted through the autosomal pattern, and the prevalence of the 
female sex remained constant (ratio F:M approximately 2:1) in both WT and MUT groups. Moreover, 
most CMs developed in females in both genotyped groups. Caucasian women seem more susceptible to 
CM, particularly in younger age groups, as confirmed by international European statistics [3,11,16].	
Recently, Taylor et al. conducted a multicentre study that included 1928 ethnically different patients. 
Although most patients, regardless of mutational status, had fair or very fair skin, and the authors
observed statistically significant differences between pathogenetic and WT/non-pathogenic CDKN2A 
mutation carriers with respect to sun burning and skin type [36,37]. In contrast with these findings, in 
our series, we did not find a significant difference in terms of skin type between MUTs and WTs. In 
our patients, the phototype distribution is comparable to that of the Mediterranean area population, 
regardless of CDKN2A gene status [15]. This finding could depend on the fact that the CDKN2A gene 
encodes two distinct proteins (p16INN4 p16INK4a and p14ARF) that act as tumour suppressors, while 
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they have no direct influence on the skin phototype. Nevertheless, it is well known that a light 
phototype and the presence of MCR1 variants (RHC, associated with red hair and fair skin) 
significantly increase penetrance of CDKN2A pathogenic mutations [13,27]. Our data are consistent 
with those published by Aguilera et al., presumably because the two populations share a common 
ethnic origin (Mediterranean descent) [2]. 	
A high number of melanocytic nevi (>50) and a history of a previous excision of dysplastic nevi, which 
are identifiable in 7-20% of the European general population, are established risk factors for CM, 
especially in familial melanoma kindred. Our study reveals that CDKN2A carriers, compared to both 
WT patients to the Caucasian general population, have a higher number of dysplastic nevi. Conversely, 
the number of common melanocytic nevi is not significantly different compared to WT subjects 
[20,38,39].	
A family history of CM is an important indicator of FCS, in particular of a CDKN2A germline
mutation. According to the literature data, in our study, the likelihood of detecting CDKN2A germline 
mutation increases with a positive family history of CMs and with the number of family members 
affected by this cancer [34,35]. The percentage of patients with a positive family history of CMs is 
significantly higher among MUTs than CDKN2A-negative cases (78.1% MUT vs 29% WT, P<0.001). 
Moreover, the CDKN2A gene mutation rate was 40.5% for patients with 2 family members with CM 
and reached 60% for patients with > 3 affected family members. A family history of both CM and PC 
(9/132) is also associated with a high probability of CDKN2A germline mutations (MUT 7/32, 21.9% 
vs WT 2/100, 2% P<0.001), while a family history of PC alone without family members with CMs 
(12/132) seems to be less indicative of germline mutations of the CDKN2A gene (MUT 4/32, 12.5% vs 
WT 8/100 8% P=0.441). 	
It is well known that younger onset of CM is clearly a consequence of CDKN2A mutation. In effect, the 
majority (60.5%) of all CMs in MUTs has been diagnosed by 40 y, and only MUT patients developed
CMs before 20 y of age. Nonetheless, because of selection criteria for genetic testing, both MUT and 
WT index cases showed a higher risk for developing CM earlier (10 to 20 y) than the general 
population (worldwide mean age: 50 y). Moreover, MUT patients developed CMs without statistically 
significant anticipation compared to individuals from high-risk melanoma kindred without a mutation 
(WT). According to the literature, early onset (< 40 y) of the first CM alone without family or personal 
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history indicative of FCS is not related to a high likelihood of an identifiable mutations on the 
CDKN2A gene [6,34,35,37].	
It is known from the literature that CDKN2A mutation carriers tend to develop a higher number of 
MPMs than non-carriers [17,24,27]. This clinical feature is also evident in our experience. MUTs 
developed a higher number of primary tumours compared both to WT individuals (52% vs 16% 
P<0.001) and the general Caucasian population (worldwide data 1.3-8.5%) [17]. They also generated 
skin tumours subsequent to the first with a longer time interval than WTs (data not reported by study 
summarized in Table 1), despite the fact that we did not find a statistically significant difference.  
We also confirmed the well-known difference in the anatomical distribution of CMs between woman 
and men. Indeed, the body sites most frequently involved in WT female patients were lower limbs and 
trunk, while WT male patients developed CMs mainly on the trunk (P=0.008, data in accordance with 
those from the general population) [9]. In contrast, this gender difference disappears if we consider
MUT patients (P=0.685). To date, only Aguilera et al. demonstrated differences in tumour localization 
between CDKN2A carriers and control patients, although data on gender differences are missing [2]. 
Finally, our study provides evidence that CM localization in CDKN2A mutation carriers appears to be 
independent of gender. Moreover, MUTs showed a discordance between the anatomical site of the 
MPMs in the majority of cases (77.8%) compared to WT patients (47.3%), even though it was not a 
statistically significant difference (P=0.057). This finding has also been reported by several authors 
[32,39]. Therefore, we could hypothesize that the anatomical distribution of CMs in carriers of an 
autosomal dominant CDKN2A germline mutation (which confers a constitutional risk to the entire skin 
surface) might be independent of gender and could be influenced by other factors such as intermittent 
exposure to UV rays on the trunk and lower limbs. Conversely, the penetrance of the CDKN2A 
mutation (in terms of risk of developing CM) appears to be higher among females, as confirmed 
previously by other authors (Table 1) [2,25,31,36,39].
Several previous publications have shown that CDKN2A carriers tend to develop SSMs and in situ 
CMs more frequently than NMs and LM/LMMs (Table 1). These histological features were also found 
in our study, without significant differences between genotyped groups (P=0.512), even if we stratified 
data for specific anatomical sites, except for the head and neck region. Here, there was a prevalence of 
SSMs in carriers of CDKN2A mutations compared to WTs (100% vs 16.7%, P=0.006). Conversely, 
LM-LMMs (CMs typically related to the oldest patients) were represented only in the WT group. Even 
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if we consider that these skin tumours were diagnosed in the MUT and WT groups at the same mean 
age (43 y), these differences could be attributable to the phenotypic characteristics of the genetic 
syndrome. We also highlighted that MUT subjects developed in situ tumours not only more frequently 
that WT patients (13.4% vs 8.9%) but also earlier, with an average anticipation of 10 years (P=0.105). 	
Our data confirm the well-known predisposition of mutation carriers to develop invasive CMs with 
Breslow depths (P=0.023) and Clark levels (P=0.002) significantly lower than WTs, as previously 
reported by other authors (Table 1). Stratifying data on the basis of the time of diagnosis, differences in 
terms of Clark level were confirmed for all CMs (first P=0.029 and subsequent to the first CMs 
P=0.005). With regard to Breslow depth, these differences may be attributable only to invasive CMs 
(SSMs) diagnosed after the first (SSMs P=0.015). Indeed, the N_CM1 of MUTs showed a Breslow 
thickness higher than that of WT patients, regardless of histological subtype (although there was no 
evidence of a statistically significant difference). For NMs, we did not observe a statistically significant
difference between the two genotyped groups in terms of Breslow depth (P=0.926) and ulceration 
(P=0.868). To the best of our knowledge, these findings have never been reported before.  	
Moreover, among CMs subsequent to the first, in situ tumours developed more frequently in WT 
patients (17.9% vs 42.1%, P=0.068, Table 6). Since all patients, regardless of mutational status, 
underwent an identical follow-up schedule based on AJCC staging, we hypothesized that this 
difference might have been determined by the longer mean interval of time between MPMs in MUTs 
compared to WTs. Specifically, 27.7% of N_CM2 in MUTs (vs 18.75% of WT) was diagnosed > 5 y 
from the first one, when the frequency of physical examinations during the scheduled follow-up 
decreases. These findings emphasize the crucial role of constant dermatological surveillance, which 
should be personalized according to mutational status, and it is more important in these high-risk 
patients to start as early as possible, even for carriers with a negative personal history of CM. 	
There are few published data on the histological characteristics of CMs developed by CDKN2A
mutation carriers in terms of tumour ulceration, mitotic rate and regression (Table 1).  
For tumour ulceration, in contrast to other data published previously, in our series, the percentage of 
ulcerated CMs was significantly lower in MUTs than WTs. These differences were significant only in 
SSMs, whereas we did not find significant differences between NMs developed by MUT and WT 
patients [31]. In contrast, in our experience, there were no significant differences in mitotic rate or 
regression comparing invasive CMs from MUTs and WTs. The majority of CMs had mitotic rate < 
14		
1/mm2 and showed no regression, regardless of mutation status. These data were in agreement with 
those in the literature [2,31].	
To our knowledge, there are no published data that compare SLNB involvement between MUT and 
WT patients. In our experience, although the percentage of patients who meet inclusion criteria for this 
staging procedure were similar in both genotyped groups (P=0.436), there was a greater prevalence of 
sentinel node metastases (SNM) in WT compared to MUT patients (18.2% vs 0%; P=0.302). These 
data could be attributable to major prognostic factors, such as the presence of tumour ulceration (17/22, 
75% WT vs 0/5, 0% MUT P=0.003) and greater thickness (> 1 mm in 100% WT 22/22 vs 20% 1/5 
MUT P<0.001) in WT patients. 	
In conclusion, our study confirms that CDKN2A carriers developed CMs with distinctive features 
compared to WT/non-pathogenetic CDKN2A mutation carriers. They developed in situ and invasive 
CMs with younger onset compared to the general population. Compared to WTs, MUT patients
generated in situ CMs and metachronous CMs at a lower median age (approximately 10 years earlier). 	
In comparison to WTs, MUT patients generated a higher number of dysplastic nevi. These data would 
suggest that melanomagenesis in CDKN2A mutation carriers occurs most often by malignant 
transformation of pre-existing melanocytic precursors (dysplastic melanocytic nevi) rather than from 
apparently healthy skin (de-novo event). 	
MUT subjects generated a significantly higher number of MPMs. They also had discordance in the 
anatomical site and a longer time interval, though we did not find statistically significant differences 
with respect to WT. 	
Anatomical distribution of CMs in MUT patients appears to be independent of gender, contrary to 
WTs. However, female patients seem more susceptible to the development of CM regardless of 
CDKN2A gene status. 	
MUTs developed SSMs and in situ CMs more frequently, while NMs were rare. The number of SSMs
on the head/neck region was significantly higher compared to WTs.	
For histological findings, MUTs developed SSMs with distinctive characteristics compared to WTs. In 
detail, SSMs generated by MUT subjects had lower Clark level (for all invasive CMs, regardless of 
time of diagnosis), lower Breslow thickness (for CMs subsequent to the first) and less frequent 
ulceration. Conversely, as regard NMs, we did not observe a statistically significant difference between 
15		
the two genotyped groups in terms of Breslow thickness and ulceration. NMs developed only as first 
tumours both in MUT and in WT patients.	
CDKN2A carriers rarely developed CMs with regression and high mitotic rate, without statistically 
significant differences compared to non-carriers. 	
Since germline mutation of the CDKN2A gene segregates independently from skin phototype, we did 
not find a significant difference in terms of skin type between MUTs and WTs, in contrast to reports by 
other authors.	
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We submitted tables as separate “Table”-files
Table 1 - Summary of phenotypic, histopathological and genetics aspects of melanoma CDKN2A mutation carriers versus WT 
melanoma CDKN2A patients (data from largest published series). 
 Taylor et al.  Van Der Rhee et al.    Sargen et al.   Aguilera et al.    Masback et al. 
 
 
CDKN2A 
mutation carriers 
670 patients  
(1258 patients CDKN2A-
Wild-Type) 
182 patients  
(127 positive and 55 not 
tested) 
7512 control melanoma 
 
123 patients   17 patients    26 patients  78 controls 
Geographical 
Origin 
 
GenoMel Consortium: 
Australia, Austria, France, 
Germany, Italy, Latin 
America, Latvia, Spain, 
Sweden, Netherlands, UK, 
USA 
Netherlands 
 
GenoMEL 
Consortium: USA, 
Australia, UK, Spain, 
Italy, Netherlands 
 
Spain  Southern Sweden 
GENDER  Unspecified  M 44% F 56% 
NS 
MUT vs  
control 
 
Unspecified  M 35.3% F 64.7%  NS  M 46% F 54% 
SKIN TYPE 
Brown/Olive  
11% 
Fair  
68% 
Very fair  
21% 
P=0.04  Unspecified 
 
Unspecified 
Fototype     
I-II: 42.9% 
Fototype     
III-IV: 
57.1% 
NS 
MUT vs 
WT  Unspecified 
DYSPLASTIC 
NEVI  Unspecified  Unspecified 
 
Unspecified  Unspecified  Unspecified 
COMMON 
MELANOCYTIC 
NEVI  Unspecified  Unspecified 
 
Unspecified  Unspecified  Unspecified 
AGE 
AT 
DIAGNOSIS 
Of CM 
 
<30 y  
25% 
30-39 y
30% 
40-49 y
21% 
50-59 y
14% 
60-69 y  
7% 
> 70 y  
3% 
P<0.0001 
MUT vs 
WT   Mean 39 y 
P<0.001  
MUT vs  
control  
 
Unspecified  Mean  37.51 y  P<0.05  Mean 43.5 y 
MPMs   Yes 48% 
No 52% 
 
P<0.0001 
MUT vs 
WT 
40.7%  NS   MUT vs  
control 
 
Unspecified  64.7%  P<0.005  Unspecified 
ANATOMIC 
DISTRIBUTION 
OF CMs  Unspecified 
M 
Head/Neck 
14.4% 
Trunk  
54.3% 
Upper limbs 
13.8% 
Lower 
limbs 
17.6% 
F 
Head/Neck 
10.9% 
Trunk 
29.4% 
Upper 
limbs 
18,9% 
Lower 
limbs 
40.8% 
 
NS 
Head/Neck   
NS 
Trunk        
NS 
Upper 
limbs  
NS 
Lower 
limbs 
MUT vs  
control  
 
Unspecified 
Head/Neck  
0% 
Trunk  
47% 
Upper 
limbs  
5.9% 
Lower 
limbs 
47.1% 
Palms 0% 
Soles 0% 
P=0.015 
MUT vs 
WT 
Head/Neck  
15% 
Trunk  
46% 
Upper and 
lower limbs 
35% 
Palms, Soles, 
and Nails 4% 
DISCORDANCE 
OF BODY SITE 
FOR MPMs  Unspecified  63.9%  P<0.001 
 
Unspecified  Unspecified  Unspecified 
HISTOLOGICAL 
SUBTYPE 
SSM 73% 
NM 6% 
LMM 2%  P=0.003 
SSM/In situ 
88.9% 
NM  
7.6% 
LMM/LM 
2.1% 
 
SSM/In situ OR (95% 
CI) =1 
NM 
P<0.001* 
LMM/LM 
P<0.001* 
SSM 91% 
NM 1.6% 
LMM 5.7% 
In Situ  
58.8%  
Invasive CMs  
42,2% 
SSM  
100%  
Other subtype  
0% 
BRESLOW 
THICKNESS/ 
INVASIVENESS 
In situ:16% 
0.01-
1.00:62% 
1.01-
2.00:14% 
2.01-4.00: 
6% 
> 4,00: 2% 
P=0.03 
MUT vs 
WT  
In situ 
22% 
Invasive 
78% 
NS 
MUT vs  
control  
 
Unspecified  Mean 0.74 mm  P<0.005 
Mean  
1.58 
mm 
 
NS 
TABLES
CLARK LEVEL  Unspecified  Unspecified 
 
Unspecified  Unspecified 
II  
46% 
III  
31% 
IV  
19% 
V  
4% 
P=0.04 
ULCERATION  Unspecified  Unspecified 
 
Yes 
2.4% 
No 
97.6% 
NS  
MUT vs 
WT 
NS 
MUT vs 
Sporadic 
cases 
NS 
MUT vs 
WT and 
Sporadic 
cases 
Unspecified 
Yes 
27% 
No 
73% 
NS 
MITOTIC RATE  Unspecified  Unspecified 
 
<1/mm2 
77% 
>1/mm2 
23% 
NS 
MUT vs 
WT 
P<0.0001  
MUT vs 
Sporadic 
cases 
P<0.0001  
MUT vs 
WT and 
Sporadic 
cases 
<1/mm2 
13 (76.5%) 
>1/mm2 
4 (23.5%) 
 
NS 
MUT vs 
WT  Unspecified 
REGRESSION  Unspecified  Unspecified 
 
No 78% 
Yes 22% 
NS  
MUT vs 
WT
NS 
MUT vs 
Sporadic 
cases 
NS 
MUT vs 
WT and 
Sporadic 
cases 
No 88.2% 
Yes 11.8% 
NS 
MUT vs 
WT 
No 
69% 
Yes 
31% 
 
NS 
SENTINEL 
NODE BIOPSY 
AND SENTINEL 
NODE 
METASTASES 
Unspecified  Unspecified 
 
Unspecified  Unspecified  Unspecified 
FAMILY 
HISTORY OF 
CM AND PC  Unspecified  Unspecified 
 
Unspecified  Unspecified  Unspecified 
GENETIC 
ANALYSIS 
PERFORMED 
(Susceptibility 
genes analyzed) 
CDKN2A  
MC1R  
No data 
about 
CDK4, 
MITF, 
promoter of 
TERT, 
BAP1,POT1 
CDKN2A 
No data 
about 
CDK4, 
MITF, 
promoter of 
TERT, 
BAP1, 
POT1, 
MC1R 
 
CDKN2A 
No data 
about 
CDK4, 
MITF, 
promoter 
of TERT, 
BAP1, 
POT1, 
MC1R 
CDKN2A 
No data 
about 
CDK4, 
MITF, 
promoter 
of TERT, 
BAP1, 
POT1, 
MC1R 
CDKN2A 
Notes: only significant values are reported (P<0.05); NS  indicates not significant value.  
 
Table 2 - Inclusion criteria to genetic test that strongly suggest a FCSa related to melanoma susceptibility genes 
Histologically-proven diagnosis of one or more CM and at least one of the following criteria 
CM diagnosed < 40 years old  
Multiple Primary CMs  
Family history of CM  
Personal and/or family history of non-cutaneous cancers suggestive of FCS related to germline mutations of CDKN2A, CDK4, 
MITF and BAP1 genes 
Note a: Familial Cancer Syndrome (FCS) is defined as a hereditable predisposition to a specific pattern of different cancers types 
and body-sites, aggregating within families, which typically occur as multiple primary malignancies at an earlier age respect the 
general population. 
 
 
Table 3  – Phenotypic features of our patients (MUT versus WT) compared to literature data 
 
CLINICAL  
FEATURES 
 
MUT 
(patients =32 CMs=60)  WT (patients =100 CMs=119) 
 
P-Value 
MUT  
vs  
WT 
Previous published data about 
CDKN2A mutation carriers 
(Table 1) 
 
GENDER 
 
 
 
 
 
 
 
 
  Patients   CMs 
F  21 65.7%  43 71.7% 
M  11 34.3%  17 28.3% 
Tot  32 100%  60 100% 
 
 
 
 
 Patients  CMs 
F  67 67%  81 68% 
M  33 33%  38 32% 
Tot  100 100%  119 100% 
 
 
Patients 
M vs F 
MUT 
P=0.05 
WT 
P<0.001* 
 
CMs  
M vs F  
MUT 
P=0.005 
WT 
P<0.001* 
 
Gender 
Patients 
MUT vs WT 
NS 
 
Gender  
CMs  
MUT vs WT 
NS 
 
CONCORDANCE 
Predominance of Female 
regardless genotype 
 
SKIN PHOTOTYPE 
Ethnic origin of our patients: 
caucasian  
 Patients  % 
I  0  0 
II  8  25 
II  19  59,4 
IV  5  15,6 
V  0  0 
VI  0  0 
Tot  32  100 
 
 Patients  % 
I  0  0 
II  19  19 
II  65  65 
IV  16  16 
V  0  0 
VI  0  0 
Tot  100  100 
 
NS 
 
DISCORDANCE 
depending on ethnic origin of 
study population 
DYSPLASTIC NEVI  62.5%  26%  P<0.001 
No data  
Van Der Rhee cited other references 
that support high frequency of 
dysplastic nevi in familial melanoma 
[39] 
COMMON MELANOCYTIC 
NEVI 
 
N  Patients  % 
<10  1  3.1 
>10 
<50  20  62.5 
>50  11  34.4 
Tot  32  100 
 
N  Patients  % 
< 10  17  17 
> 10 
< 50  56  56 
>  50  27  27 
Tot  100  100 
 
NS  No data  
 
MEDIAN AGE AT 
DIAGNOSIS OF CMs 
 
All CMs 
41.5 y 
(IQR 33.5-49.0 y) 
60.5% < 40 y 
39.5% > 40 y 
 
N_CM1  
First CM 
regardless subtype 
39.5 y 
(IQR 30.5-45.0 y) 
 
In situ  
34.5 y 
(IQR 23.0-40.0 y) 
 
N_CM1.5 
29.0 y 
(IQR 24.0-34.0 y) 
 
 
 
All CMs 
38.0 y 
(IQR 32.0-45.0 y) 
45% < 40 y 
55% > 40 y 
 
N_CM1  
First CM 
regardless subtype 
37.0 y 
(IQR 30.5-44.0 y) 
 
In Situ 
43.0 y 
(IQR 37.5-47.5y) 
 
N_CM1.5 
43.0 y 
(IQR 39-51 y) 
 
 
All CMs 
NS 
 
N_CM1 
First CM 
regardless 
subtype 
NS 
 
In situ 
NS 
 
N_CM1.5 
NS 
CONCORDANCE 
Young onset of CM 
 
 
MULTIPLE PRIMARY 
CMs 
(MPMs) 
MPMs 
52% 
Mean CMs per patient 
1.88 
 
 
MPMs 
16% 
Mean CMs per patient 
1.18 
 
 
 
 
P<0.001 
 
 
CONCORDANCE 
Higher number of MPMs 
INTERVAL OF TIME (mean, 
months) 
BETWEEN THE 
DIAGNOSIS OF MPMs 
N_CM1 and N_CM2 
53.2 
N_CM2 and N_CM3 
40.5 
N_CM3 and N_CM4 
54 
 
N_CM1 and N_CM2 
27 
N_CM2 and N_CM3 
21.3 
N_CM3 and N_CM4 
---  
none developed 4 CMs 
 
N_CM1
and 
N_CM2 
NS 
N_CM2 
and 
N_CM3 
NS 
 
No data  
 
ANATOMIC 
DISTRIBUTION 
of CMs 
For more details see Table 4  
 
 
Regardless of gender 
 
 
Gender differences 
MUT 
(F vs M) 
NS 
WT 
(F vs M) 
P=0.008 
 
CONFLICTING DATA 
depending on the case series 
 
 
DISCORDANCE OF BODY 
SITE of MPMs 
 
 
77.8%   47.3%  NS 
CONCORDANCE 
limited data available  
[39] 
Notes: only significant values are reported (P<0.05); NS indicates not significant value. 
 
 
 
 
 
 
 
 
 
 
 
Table 4  - Anatomical Site of CMs in MUT and WT patients  
Anatomical 
Site of CMs 
All 
MUT 
60 
All  
WT 
112 
MUT 
vs 
WT 
(regardless 
of gender) 
NS 
MUT F 
43  MUT M 17 
MUT  
M 
vs 
F 
NS 
 
WT F 
74
WT M 
38 
WT 
M 
vs 
F 
P=0.008 
 
 
Trunk 
26 
43.3% 
I 
54 
48.2% 
I 
17 
39.5% 
I 
9 
53% 
I 
31 
41.9% 
I 
23 
60.5% 
I 
Lower Limbs 
16 
26.7% 
II 
35 
31.3% 
II 
12 
28% 
II 
4 
23.4% 
II 
31 
41.9% 
I 
4 
10.5% 
III 
Upper Limbs 
11 
18.3% 
III 
17 
15.2% 
III 
9 
21% 
III 
2 
11.8% 
III 
9 
12.2% 
II 
8 
21.1% 
II 
Head and 
Neck 
5 
8.4% 
IV 
6 
5.3% 
IV 
3 
7% 
IV 
2 
11.8% 
III 
3 
4% 
III 
3 
7.9% 
IV 
Acral sites 
2 
3.3% 
V 
0 
0% 
V 
2 
4.5% 
V 
0 
0% 
IV 
0 
0% 
IV 
0 
0% 
V 
Notes: only significant values are reported (P<0.05); NS indicates not significant value. 
 
 
Table 5 –   Histopathological features of our patients (MUT versus WT) compared to literature data 
HISTOPATOLOGICAL 
FEATURES 
 
MUT 
(patients =32 CMs=60)  WT (patients =100 CMs=119) 
P-Value 
MUT 
vs 
WT 
Previous published 
data about 
CDKN2A mutation 
carriers 
(Table 1) 
HISTOLOGICAL 
SUBTYPE§     
SSM  45 77.6%  74 69.1% 
NS 
CONCORDANCE 
SSM and In situ are 
the most frequently 
histological subtype 
 
In Situ  8 13.8%  16 14.9% 
NM  3 5.2%  13 12.2% 
Other  2 3.4%  4 3.8% 
For more details see Table 6  § Missing 2/60 3.3%  § Missing 12/119 10% 
Concordance of Histological 
Subtype for MPMs  63.2%  70.8%  NS  No Data 
BRESLOW THICKNESS     
BRESLOW THICKNESS 
Median of all invasive CMs  0.4 mm  0.57 mm  P=0.023 
CONCORDANCE 
Breslow thickness 
significantly lower 
BRESLOW THICKNESS 
Mean of all invasive SSM  0.67 mm  0.82 mm  NS  No Data 
BRESLOW THICKNESS 
Mean of first invasive CMs 
  
Regardless subtype  
1.04 mm  Regardless subtype  0.99 mm  NS  No Data 
SSMs 
0.96 mm  SSMs 0.84 mm  NS  No Data 
NMs 
1.73 mm  NMs 1.77 mm  NS  No Data 
 
BRESLOW THICKNESS 
Mean of invasive CMs 
subsequent to the first 
 
  
SSMs 
0.37 mm  SSMs 0.73 mm  P=0.015  No Data 
NM 
None  NM None  -  No Data 
 
CLARK LEVEL 
 
  
 
CLARK LEVEL 
of all invasive CMs§ 
II 
34 69.4%  II 38 39.2% 
 
P=0.002 
CONCORDANCE 
limited data 
available 
[25] 
III 
14 28.6%  III 38 39.2% 
IV 
1 2%  IV 20 20.6% 
V 
0 0%  V 1 1% 
§ Missing 2/51 3,9%  § Missing 3/101 2.9% 
CLARK LEVEL 
of first invasive CMs§ 
II 
14 53.9%  II 29 37.7% 
P=0.029  No Data 
III 
11 42.3%  III 32 41.6% 
IV 
0 0.0%  IV 15 19.5% 
V 
1 3.9%  V 1 1.3% 
§ Missing 2/28 7.1%  § Missing 2/90 2.2% 
 
CLARK LEVEL 
of invasive CMs subsequent to 
the first§  
 
II 
20 87.0%  II 4 40.0% 
P=0.005  No Data 
III 
3 13.0%  III 3 30.0% 
IV 
0 0.0%  IV 3 30.0% 
V 
0 0.0%  V 0 0.0% 
§ Missing 0/23 0%  § Missing 1/11 9% 
ULCERATION    
 
ULCERATION 
of all invasive CMs§ 
Overall CMs 
1.8% 
SSMs 
0% 
NMs 
33% 
Overall CMs 
11.9% 
SSMs 
9,5% 
NMs 
38% 
Overall 
CMs 
P=0.028 
SSMs 
P=0.036 
NMs 
NS 
 
DISCORDANCE 
limited data 
available 
[25,31] 
§Missing 4/51 7.8%  §Missing 16/101 15.8% 
ULCERATION 
of first invasive CMs§ 
Overall CMs 
1 4.0% 
SSMs 
0 0% 
NMs 
1 4% 
Overall CMs 
10 13.3% 
SSMs 
6 8% 
NMs 
4 5,3% 
 
Overall 
CMs 
NS 
No Data 
§Missing 3/28 10.7%  §Missing 15/90 16.6% 
ULCERATION 
of invasive CMs subsequent to 
the first§ 
 
Overall CMs 
0 0.0% 
SSMs 
0 0% 
Other subtypes 
0 0% 
NMs 
None of the invasive CMs 
subsequent to the first was 
NM
 
Overall CMs 
1 10.0% 
SSMs 
1 10% 
NMs and other subtypes  
None (all the of the 
invasive CMs subsequent to 
the first were SSMs) 
 
Overall 
CMs  
NS  No Data 
§Missing 1/23 4.3%  §Missing 1/11 9% 
MITOTIC RATE 
< 1/mm2    
MITOTIC RATE 
< 1/mm2 
of all invasive CMs 
74%  67%  NS 
 
CONCORDANCE 
Majority of CMs 
with Mitotic 
rate<1/mm2 
regardless of 
mutation status 
MITOTIC RATE 
< 1/mm2 
of first invasive CMs§ 
7 58.3%  36 64.3% 
NS  No  data 
§Missing 16/28 57.1%  §Missing 35/90 38.8% 
MITOTIC RATE 
< 1/mm2 
of invasive CMs subsequent to 
the first§ 
7 100%  7 100% 
-  No data 
§Missing 16/23 69.5%  §Missing 4/11 36.3% 
REGRESSION      
REGRESSION 
of all invasive CMs  7.3%  7%  NS 
 
CONCORDANCE 
Majority of CMs 
with no regression 
regardless of 
mutation status 
 
REGRESSION 
of first invasive CMs§ 
2 11.1%  3 4.6%  NS  No  data §Missing 10/28 35.7%  §Missing 25/90 27.7% 
REGRESSION 
of invasive CMs subsequent to 
the first§ 
0 0.0%  1 14.3% 
NS  No  data 
§Missing 6/23 26.0%  §Missing 4/11 36.3% 
SENTINEL NODE BIOPSY 
And 
SENTINEL NODE 
METASTASES 
SLNB 
5/32 
15.6% 
SNMs 
0/5 
0% 
SLNB 
22/100 
22% 
SNMs 
4/22 
18.2% 
SLNB 
NS 
SNMs 
NS 
No Data 
Notes: only significant values are reported (P<0.05); NS  indicates not significant value; § indicates missing data.  
 
Table 6 - Histological Subtypes of invasive and In situ CMs in relation to mutational status (MUT vs WT)  
 
ALL INVASIVE CMs 
138 
49 MUT (+2§) 89 WT (+12§) 
FIRST CMs 
119 (+13§) 
30 MUT (+ 2§) 89 WT (+11§) 
CMs subsequent to the first * 
47(+1§) 
28 MUT 19WT(+1§) 
SSM 
NS
 
NM 
NS
 
Other 
INVASIVE CMs 
26 MUT 
79 WT 
IN SITU 
4 MUT
10 WT  SSM 
NS
 
IN SITU 
NS
 
Other 
SSM 
NS
 
NM 
NS
 
Other   
M
U
T 
45/49 
92%  3/49 6%  1/49 2%  23/26 88.5%  3/26 11.5%  0/26 0%  4/30 13.4% 
NS
 
22/28 
78.6% 
 
5/28 
17.9% 
1/28 
3.5% 
W
T  74/89 83%  13/89 15%  2/89 2%  64/79 81%  13/79 16.5%  2/79 2.5%  10/89 11.2%  10/19 52.6%  8/19 42.1% 
 
1/19 
5.3% 
Notes: only significant values are reported (P<0.05); NS indicates not significant value; § indicates missing data about 
histological subtypes; *: in this group, we have not detected NMs. 
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SUPPLEMENTARY MATERIALS
 
Online Resource 1 – Germline mutations and variants in CDKN2A genes identified in our study  
CDKN2A  
Germline  
Mutations 
CDKN2A  
Mutation  
Carriers  
(Probands) 
c.301G>T (p.Gly101Trp)a  24 
c.458-2415_471+284del 
(p.Asp153AlafsX30)b  3 
c.71G>C (P.Arg24Pro)  3 
c.259C>T (p.Arg87Trp)  1 
c.142C>A (p.Pro48Thr)  1 
c.270C>G (p.Phe90Leu)c  1 
Tot  33 
Note a: The most common worldwide CDKN2A mutation identified to date with a particularly high occurrence in 
France and Italy, due to an ancient founder effect 
Note b: CDKN2A germline mutation, which was never previously described 
Note c: The patient developed three MPMs (diagnosed between 55 and 62 years of age), bilateral ovarian cancer 
(papillary serous cystoadenoma, at 38 years of age) and invasive ductal carcinoma of the left breast at 59 years of age. 
The family history was negative for CM, while was positive for endometrial (mother), gastric (maternal grandfather) 
and ocular (not further specified, maternal uncle) cancers. She carries a CDKN2A missense variant, which was never 
previously described in melanoma pts, while it has been identified as somatic mutation in ovarian and endometrial 
cancers. Miller at al. published in 2011 a study in which an in vitro functional test showed a significant reduction of the 
ability of cell cycle arrest in G1 phase (about 30%), like that of the founder germline mutation c.301G>T. [26].   
Note d: Carriers’ first (FDRs: parents, siblings and children) and second degree (SDRs: grandparents, uncles/aunts, half-
siblings, nieces/nephews and grandchildren) relatives who underwent genetic analysis 
Note e: Carriers’ FDRs and SDRs non-genotyped because they rejected genetic analysis or untraceable or deceased 
 
